- Trials with a EudraCT protocol (16)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
16 result(s) found for: Adrenergic Receptor.
Displaying page 1 of 1.
| EudraCT Number: 2005-004060-24 | Sponsor Protocol Number: Glaucoma Xalacam /Combigan | Start Date*: 2005-11-24 |
| Sponsor Name:Department of Clinical Pharmacology | ||
| Full Title: A double-masked randomized cross-over study comparing the effect of Xalacom (latanoprost/timolol) and Combigan (brimonidine/timolol) fixed combination on intraocular pressure and ocular blood flow ... | ||
| Medical condition: Glaucoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-004059-34 | Sponsor Protocol Number: C7Q040 | Start Date*: 2021-02-25 | |||||||||||
| Sponsor Name:Leiden University Medical Center | |||||||||||||
| Full Title: Stimulation of the beta-2 adrenergic receptor for activating human brown adipose tissue | |||||||||||||
| Medical condition: Obesity, overweight, lipid- and glucose metabolism | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-006861-18 | Sponsor Protocol Number: 20061212 | Start Date*: 2007-03-26 |
| Sponsor Name:Department of Cardiology | ||
| Full Title: Comparison between beta-adrenergic blockers and angiotensin II receptor antagonists for the treatment of late hypertension in patients with repaired aortic coarctation | ||
| Medical condition: Aortic coarctation and late hypertension | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-001413-14 | Sponsor Protocol Number: 205.416 | Start Date*: 2008-08-20 | |||||||||||
| Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
| Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 ... | |||||||||||||
| Medical condition: Patients with severe persistent asthma who are still symptomatic despite being treated with high-dose inhaled corticosteroids and long-acting beta2-agonists. Additional asthma treatments are allowe... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) NL (Completed) IT (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-001414-25 | Sponsor Protocol Number: 205.417 | Start Date*: 2008-08-20 | |||||||||||
| Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
| Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 ... | |||||||||||||
| Medical condition: Patients with severe persistent asthma who are still symptomatic despite being treated with high-dose inhaled corticosteroids and long-acting beta2-agonists. Additional asthma treatments are allowe... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) NL (Completed) IT (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002069-52 | Sponsor Protocol Number: 4045-301 | Start Date*: 2017-01-23 | |||||||||||
| Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
| Full Title: A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy | |||||||||||||
| Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) SE (Completed) DE (Completed) FR (Ongoing) ES (Trial now transitioned) CZ (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) DK (Trial now transitioned) GR (Completed) NO (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-000832-82 | Sponsor Protocol Number: GLYCEMIA-Heart | Start Date*: 2018-09-13 | |||||||||||||||||||||
| Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | |||||||||||||||||||||||
| Full Title: GLYcemic Control with EMpagliflozin vs standard of care in patients with type 2 dIAbetes and Heart failure: effects on cardiac remodeling and neurohormonal activation | |||||||||||||||||||||||
| Medical condition: Heart failure and type 2 diabetes mellitus | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2004-002762-38 | Sponsor Protocol Number: Clin-AGI001-001 | Start Date*: 2005-04-13 | |||||||||||
| Sponsor Name:AGI Therapeutics Limited | |||||||||||||
| Full Title: A randomised, double-blind, placebo-controlled study of AGI 001 in the treatment of functional dyspepsia | |||||||||||||
| Medical condition: Functional (Non-ulcer) Dyspepsia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LT (Completed) GB (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-019798-13 | Sponsor Protocol Number: MB102-077 | Start Date*: 2011-03-04 | ||||||||||||||||
| Sponsor Name:Bristol Myers Squibb International Corporation | ||||||||||||||||||
| Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Co... | ||||||||||||||||||
| Medical condition: Type 2 diabetes with inadequate glycemic control and inadequately controlled hypertension | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) HU (Completed) DE (Completed) FI (Completed) DK (Completed) IE (Completed) CZ (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2005-005615-21 | Sponsor Protocol Number: 205.341 | Start Date*: 2006-07-13 | |||||||||||
| Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
| Full Title: A Randomised, Double-Blind, Placebo-Controlled, Crossover Efficacy and Safety Evaluation of 8-Week Treatment Periods of Two Doses [5 µg (2 actuations of 2.5 µg) and µg (2 actuations of 5 µg)] of Ti... | |||||||||||||
| Medical condition: Patients with severe persistent asthma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) DK (Completed) NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-005616-25 | Sponsor Protocol Number: 205.342 | Start Date*: 2006-07-31 | |||||||||||
| Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co.KG | |||||||||||||
| Full Title: A 16-week randomised, placebo-controlled, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat® inhaler (2 ... | |||||||||||||
| Medical condition: Patients with moderate persistent bronchial asthma and homozygous for arginine at the 16th position of the beta-2-adrenergic receptor | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) GB (Completed) ES (Completed) FI (Completed) BE (Completed) DK (Completed) IT (Completed) AT (Completed) GR (Completed) SK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-001994-27 | Sponsor Protocol Number: 2006B180 | Start Date*: 2007-09-03 | |||||||||||
| Sponsor Name:Academisch Medisch Centrum | |||||||||||||
| Full Title: The effect of beta-adrenergic receptor blockade on sympathetic activity and coagulation in patients with heart failure (BACH-F study) | |||||||||||||
| Medical condition: Congestive heart failure | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-001629-41 | Sponsor Protocol Number: DSC/15/2357/53 | Start Date*: 2018-11-15 | |||||||||||
| Sponsor Name:ITALFARMACO S.P.A. | |||||||||||||
| Full Title: A randomised, double-blind, placebo-controlled study to evaluate the micro-macroscopic effects on muscles, the safety and tolerability, and the efficacy of givinostat in patients with Becker Muscu... | |||||||||||||
| Medical condition: Distrofia Muscolare di Becker (DMB) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: NL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-005177-21 | Sponsor Protocol Number: 2015-29 | Start Date*: 2016-01-28 |
| Sponsor Name:Assistance Publique Hôpitaux de MARSEILLE | ||
| Full Title: Dose-Finding of Propranolol in combination with metronomic fixed oral cyclophosphamide based on Bivariate efficacy-tolerability outcome in patients with locally advanced or metastatic angiosarcoma ... | ||
| Medical condition: Patients presenting angiosarcomas disease | ||
| Disease: | ||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: FR (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-004230-14 | Sponsor Protocol Number: Clin-AGI001-002 | Start Date*: 2004-12-22 | |||||||||||
| Sponsor Name:AGI Therapeutics Limited | |||||||||||||
| Full Title: A randomised, double-blind, placebo-controlled study of AGI 001 in the treatment of irritable bowel syndrome. | |||||||||||||
| Medical condition: Irritable Bowel Syndrome | |||||||||||||
|
|||||||||||||
| Population Age: | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001645-12 | Sponsor Protocol Number: ALPHA2PREVENT | Start Date*: 2021-06-28 |
| Sponsor Name:Oslo University Hospital | ||
| Full Title: Alpha 2 adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): randomised controlled trial. | ||
| Medical condition: Postoperative delirium and cognitive decline in male and female participants aged 70+ scheduled for open heart surgery | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: NO (Trial now transitioned) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.